Evidence map›Paper›PMID 28558001›Full record

ArticlePloS one2017

Reverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus.

Amruta S Naik, Ania Owsianka, Brendan A Palmer, Ciaran J O'Halloran, Nicole Walsh, Orla Crosbie, Elizabeth Kenny-Walsh, Arvind H Patel, Liam J Fanning

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Amruta S NaikDepartment of Medicine, University College Cork, Cork, Ireland.
Ania OwsiankaMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
Brendan A PalmerDepartment of Medicine, University College Cork, Cork, Ireland.
Ciaran J O'HalloranDepartment of Medicine, University College Cork, Cork, Ireland.
Nicole WalshDepartment of Medicine, University College Cork, Cork, Ireland.
Orla CrosbieDepartment of Hepatology, Cork University Hospital, Cork, Ireland.
Elizabeth Kenny-WalshDepartment of Hepatology, Cork University Hospital, Cork, Ireland.
Arvind H PatelMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
Liam J FanningDepartment of Medicine, University College Cork, Cork, Ireland.ORCID http://orcid.org/0000-0001-6629-8418
University College Cork · IECork University Hospital · IEMRC University of Glasgow Centre for Virus Research · GB

Funding

Medical Research Council MC_U130184144Medical Research Council MC_UU_12014/2
6 · The paper itself

Abstract

The humoral immune system responds to chronic hepatitis C virus (HCV) infection by producing neutralising antibodies (nAb). In this study we generated three HCV pseudoparticles in which E1E2 glycoprotein sequence was targeted by the host humoral immune system. We used patient derived virus free Fabs (VF-Fabs) obtained from HCV genotype 1a (n = 3), genotype 1b (n = 7) and genotype 3a (n = 1) for neutralisation of HCVpp produced in this study both individually and in combination. Based on the available anti-HCV monoclonal nAb mapping information we selected amino acid region 384-619 for conformational epitope mapping. Amongst our notable findings, we observed significant reduction in HCVpp infectivity (p<0.05) when challenged with a combination of inter genotype and subtype VF-Fabs. We also identified five binding motifs targeted by patient derived VF-Fab upon peptide mapping, of which two shared the residues with previously reported epitopes. One epitope lies within an immunodominant HVR1 and two were novel. In summary, we used a reverse epitope mapping strategy to identify preferred epitopes by the host humoral immune system. Additionally, we have combined different VF-Fabs to further reduce the HCVpp infectivity. Our data indicates that combining the antigen specificity of antibodies may be a useful strategy to reduce (in-vitro) infectivity.

Indexed as

Antibodies, ViralEpitope MappingHepacivirusHepatitis C, ChronicHumansNeutralization TestsViral Envelope ProteinsVirulenceAntibodies, Viralglycoprotein E2, Hepatitis C virusViral Envelope Proteins

Identifiers

PMID28558001
PMCPMC5448734
OpenAlexW2606295382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.